Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
FUFulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc. (FULC)

NASDAQ Global Market · Currency in USD
$3.68 ▲ +0.00 (+0.00%)
At close: Oct 23, 4:00 PM ET. Market closed.
$3.67 ▼ -0.01 (-0.27%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$3.68
Open
$3.68
Day's Range
$3.64 – $3.69
52 Week Range
$2.83 – $15.74
Volume
1,064,952
Avg. Volume
1,879,425
Market Cap
$280.77M
Beta (5Y Monthly)
3.00
PE Ratio (TTM)
--
EPS (TTM)
-$1.11
Earnings Date
Oct 29, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$3.60

Profile: Fulcrum Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
9
CEO
Alexander C. Sapir

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases.

Earnings

Next report: Thu, Oct 29, 2026
EPS estimate -$0.07
DateEst.Actual
Jul 30, 2026-$0.24-$0.34Miss
Apr 27, 2026-$0.31-$0.25Beat
Feb 24, 2026-$0.31-$0.31Beat
Oct 29, 2025-$0.29-$0.31Miss
Jul 29, 2025-$0.29-$0.28Beat
May 1, 2025-$0.29-$0.28Beat

Analyst view

Consensus price target
$3.60 ▼ -2.2%
Range $3.00 – $4.00
Rating: Buy
Buy 41% · Hold 41% · Sell 18%

Get free alerts on FULC and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.